EQS-News: ZEISS VISUMAX 800 with SMILE pro software receives approval in China
|
EQS-News: Carl Zeiss Meditec AG
/ Key word(s): Regulatory Approval
JENA,(Germany), SHANGHAI, (China), | 27 February 2025 | Carl Zeiss Meditec AG “With the growing interest in laser vision correction in China, the market needs innovative technology that enhances surgical outcomes, safety and efficiency to benefit both surgeons and their patients. The availability of the ZEISS VISUMAX 800 with SMILE pro software further extends our commitment to ophthalmologists and helps to solidify the future of laser vision correction across China,” says Maximilian Foerst, Head of ZEISS Greater China. “ZEISS further sets itself apart in the China market with the availability of the VISUMAX 800 with SMILE pro software from ZEISS, providing the latest digital technology to meet the evolving needs of refractive surgeons worldwide,” said Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. “This next-generation femtosecond laser system creates data-driven insights to help surgeons better manage treatment paths for patients while supporting each surgeon’s unique practice requirements for greater workflow efficiency and performance.” The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.* Additionally, the shorter procedure time can reduce stress for surgeons and their patients. The ZEISS femtosecond laser also provides greater flexibility for the surgeon and patient, with a smaller footprint and compatibility with a variety of patient beds, adapting to the clinical environment to provide cutting-edge technology without compromise. With the availability of the VISUMAX® 800 with SMILE® pro software from ZEISS in China, surgeons can utilize a number of workflow enhancements including: the CentraLign® centration aid, a computer-controlled function for easy centration; the OcuLign® cyclotorsion adjustment to help counter cyclotorsion that may occur; and VISULYZE user nomograms to help surgeons collect and analyze patient data, while also providing detailed nomograms and enabling more control during every surgery. With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for surgeons in China. For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit https://zeiss.com/visumax800
* Data on file, myopia with optical zone 6.5 mm.
Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content.The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.
###
Contact for investors Sebastian Frericks
Contact for the press Frank Smith Mail: press.med@zeiss.com
27.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Carl Zeiss Meditec AG |
| Göschwitzer Str. 51-52 | |
| 07745 Jena, Germany | |
| Germany | |
| Phone: | +49 (0)3641 220-0 |
| Fax: | +49 (0)3641 220-112 |
| E-mail: | investors.meditec@zeiss.com |
| Internet: | www.zeiss.de/meditec-ag/ir |
| ISIN: | DE0005313704 |
| WKN: | 531370 |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2092683 |
| End of News | EQS News Service |
|
|
2092683 27.02.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 1.459,32 | 1.335,45 | 1.646,79 | 1.902,84 | 2.089,30 | 2.066,13 | 2.145,00 | |
| EBITDA1,2 | 313,03 | 237,98 | 435,20 | 466,65 | 422,19 | 327,22 | 333,00 | |
| EBITDA-Margin3 | 21,45 | 17,82 | 26,43 | 24,52 | 20,21 | 15,84 | 15,52 | |
| EBIT1,4 | 264,66 | 177,55 | 373,61 | 396,88 | 348,12 | 194,45 | 201,00 | |
| EBIT-Margin5 | 18,14 | 13,30 | 22,69 | 20,86 | 16,66 | 9,41 | 9,37 | |
| Net Profit (Loss)1 | 160,58 | 123,42 | 237,52 | 295,91 | 292,01 | 180,15 | 185,40 | |
| Net-Margin6 | 11,00 | 9,24 | 14,42 | 15,55 | 13,98 | 8,72 | 8,64 | |
| Cashflow1,7 | 219,63 | 178,53 | 362,66 | 188,20 | 250,86 | 247,32 | 255,00 | |
| Earnings per share8 | 1,79 | 1,37 | 2,64 | 3,29 | 3,25 | 2,01 | 2,08 | |
| Dividend per share8 | 0,65 | 0,50 | 0,90 | 1,10 | 1,10 | 0,60 | 0,60 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PricewaterhouseCoopers
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Carl Zeiss Meditec | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 531370 | DE0005313704 | AG | 3.629,50 Mio € | 22.03.2000 | Halten | 9F2HVHPW+8C |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 15,91 | 31,25 | 0,51 | 19,68 | 1,82 | 14,68 | 1,76 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 1,10 | 0,60 | 0,60 | 1,48% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 26.03.2025 | 12.02.2025 | 14.05.2025 | 07.08.2025 | 11.12.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -7,72% | -20,64% | -10,85% | -17,69% | +39,93% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
